Samsung Biologics, Foreign Investors Net Sell 89,310 Shares in Last 5 Days... Stock Price at 746,000 KRW (+1.5%)

As of 2:30 PM on the 15th, Samsung Biologics is trading at 746,000 KRW, up 1.5% from the previous day. The trading volume is 131,956 shares, which is about 78.8% of the previous day's volume. Samsung Biologics is known as the bio business holding company of the Samsung Group.

On July 15, Jin Heung-guk, a researcher at Korea Investment & Securities, stated, "With a strengthened position in the CMO industry, large-scale orders continue, and co-growth with the biopharmaceutical market is expected. New pipelines are continuously being added, such as the launch of the Eylea biosimilar after 2033, making the company's long-term growth prospects clearer. The current stock price has somewhat limited upside potential. However, confidence in future orders and achieving an operating profit margin of over 30% are resolving doubts about fundamentals that have been raised since the early growth stage." He set the target price for Samsung Biologics at 810,000 KRW.

Over the past five days, individual investors have net purchased 77,695 shares of Samsung Biologics, while foreigners and institutions have net sold 89,310 shares and net purchased 548 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.